Meta-Analysis
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. May 15, 2024; 16(5): 2168-2180
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.2168
Table 1 Meta-analysis of complement component proteins and clinicopathological features of colorectal cancer patients
Clinicopathological featureReferenceNo. of studiesModelPooled RR (95%CI)P valueHeterogeneity
I2 (%)
P value
CD55
Age (> 60 years old)High vs low expression2Fixed1.16 (0.92-1.45)0.2100.58
Sex (male)High vs low expression3Fixed1.09 (0.90-1.33)0.3600.51
Lymph node metastasisHigh vs low expression3Fixed1.30 (1.03-1.63)0.0300.70
DifferentiationHigh vs low expression3Fixed1.09 (0.93-1.29)0.2800.95
T3 + T4High vs low expression3Fixed1.11 (0.99-1.24)0.0800.95
M1High vs low expression3Random1.52 (0.43-5.43)0.5286< 0.001
CD59
Age (> 60 years old)High vs low expression2Fixed0.88 (0.66-1.15)0.3400.66
Sex (male)High vs low expression2Fixed0.85 (0.68-1.06)0.1400.81
Lymph node metastasisHigh vs low expression2Fixed1.53 (1.12-2.08)0.007530.14
CD46
Age (> 60 years old)High vs low expression2Fixed1.15 (0.86-1.52)0.3500.98
Sex (male)High vs low expression2Fixed0.87 (0.68-1.10)0.2400.63
Lymph node metastasisHigh vs low expression2Random0.81 (0.39-1.66)0.56830.01
DifferentiationHigh vs low expression2Fixed1.30 (1.04-1.63)0.0200.69
T3 + T4High vs low expression2Random0.75 (0.35-1.60)0.46800.03
Table 2 Potential sources of heterogeneity for association between positive expression of complement component proteins and colorectal cancer by region
Subgroup
Study number
Risk ratio (95%CI)
I2
P value
CD55
Asian216.88 (8.49-33.52)65%< 0.001
Non-Asian21.49 (0.19-11.97)88%0.71
CD59
Asian26.63 (4.06-10.82)63%< 0.001
Non-Asian31.97 (1.22-3.18)0%0.006
CD46
Asian23.66 (1.75-7.64)92%0.040
Non-Asian24.37 (1.95-9.78)0%< 0.001
Table 3 Egger’s test for complement components
StudiesEgger’s test
t
Bias
P value
CD4641.342.340.311
CD5541.026.150.414
CD595-0.09-1.150.931
C33-0.44-9.270.734